Authors:
ROSTAING L
CHATELUT E
PAYEN JL
IZOPET J
THALAMAS C
TONTHAT H
PASCAL JP
DURAND D
CANAL P
Citation: L. Rostaing et al., PHARMACOKINETICS OF ALPHA-IFN-2B IN CHRONIC HEPATITIS-C VIRUS PATIENTS UNDERGOING CHRONIC-HEMODIALYSIS OR WITH NORMAL RENAL-FUNCTION - CLINICAL IMPLICATIONS, Journal of the American Society of Nephrology, 9(12), 1998, pp. 2344-2348
Authors:
ETIENNE MC
CHATELUT E
PIVOT X
LAVIT M
PUJOL A
CANAL P
MILANO G
Citation: Mc. Etienne et al., CO-VARIABLES INFLUENCING 5-FLUOROURACIL CLEARANCE DURING CONTINUOUS VENOUS INFUSION - A NONMEM ANALYSIS, European journal of cancer, 34(1), 1998, pp. 92-97
Authors:
BEKRADDA M
CHATELUT E
CVITKOVIC E
SOULIE P
CANAL P
MISSET JL
DUPONTANDRE G
BENSMAINE MA
BUGAT R
Citation: M. Bekradda et al., PHARMACOKINETICS (PK) AND PHARMACODYNAMICS OF THE CARBOPLATIN (CBDCA)OXALIPLATIN (L-OHP) COMBINATION IN PATIENTS (PTS) WITH ADVANCED MALIGNANCIES - PRELIMINARY-RESULTS OF AN ONGOING PHASE-I TRIAL/, Annals of oncology, 9, 1998, pp. 447-447
Authors:
DOZ F
URIEN S
CHATELUT E
MICHON J
RUBIE H
ZUCKER JM
CANAL P
BASTIAN G
Citation: F. Doz et al., A LIMITED-SAMPLING METHOD FOR EVALUATION OF THE AREA-UNDER-THE-CURVE OF ULTRAFILTERABLE CARBOPLATIN IN CHILDREN, Cancer chemotherapy and pharmacology, 42(3), 1998, pp. 250-254
Authors:
GUICHARD S
CHATELUT E
LOCHON I
BUGAT R
MAHJOUBI M
CANAL P
Citation: S. Guichard et al., COMPARISON OF THE PHARMACOKINETICS AND EFFICACY OF IRINOTECAN AFTER ADMINISTRATION BY THE INTRAVENOUS VERSUS INTRAPERITONEAL ROUTE IN MICE, Cancer chemotherapy and pharmacology, 42(2), 1998, pp. 165-170
Authors:
JOQUEVIEL C
MARTINO R
GILARD V
MALETMARTINO M
CANAL P
NIEMEYER U
Citation: C. Joqueviel et al., URINARY-EXCRETION OF CYCLOPHOSPHAMIDE IN HUMANS, DETERMINED BY P-31 NUCLEAR-MAGNETIC-RESONANCE SPECTROSCOPY, Drug metabolism and disposition, 26(5), 1998, pp. 418-428
Authors:
MONSARRAT B
CHATELUT E
ROYER I
ALVINERIE P
DUBOIS J
DEZEUSE A
ROCHE H
CROS S
WRIGHT M
CANAL P
Citation: B. Monsarrat et al., MODIFICATION OF PACLITAXEL METABOLISM IN A CANCER-PATIENT BY INDUCTION OF CYTOCHROME-P450 3A4, Drug metabolism and disposition, 26(3), 1998, pp. 229-233
Authors:
GUIMBAUD R
GUICHARD S
BERTRAND V
APARICIO T
TERRET C
BUGAT R
COUTURIER D
CHATELUT E
CANAL P
CHAUSSADE S
Citation: R. Guimbaud et al., VARIABILITY OF DIHYDROPYRIMIDINE DESHYDROGENASE (DPD) ACTIVITY IN NORMAL, INFLAMMATORY AND TUMORAL TISSUES OF COLON AND LIVER IN HUMANS, Gastroenterology, 114(4), 1998, pp. 2483-2483
Authors:
MARTIN L
CHATELUT E
BONEU A
ROSTAING L
ROUSSILHES C
CASELLES O
CANAL P
Citation: L. Martin et al., IMPROVEMENT OF THE COCKCROFT-GAULT EQUATION FOR PREDICTING GLOMERULAR-FILTRATION IN CANCER-PATIENTS, Bulletin du cancer, 85(7), 1998, pp. 631-636
Citation: S. Guichard et al., CELLULAR INTERACTIONS OF 5-FLUOROURACIL AND THE CAMPTOTHECIN ANALOG CPT-11 (IRINOTECAN) IN A HUMAN COLORECTAL-CARCINOMA CELL-LINE, Biochemical pharmacology, 55(5), 1998, pp. 667-676
Citation: E. Chatelut et al., PREDICTION OF CARBOPLATIN CLEARANCE FROM STANDARD MORPHOLOGICAL AND BIOLOGICAL PATIENT CHARACTERISTICS - RESPONSE, Journal of the National Cancer Institute, 89(3), 1997, pp. 261-262
Authors:
RIVORY LP
HAAZ MC
CANAL P
LOKIEC F
ARMAND JP
ROBERT J
Citation: Lp. Rivory et al., PHARMACOKINETIC INTERRELATIONSHIPS OF IRINOTECAN (CPT-11) AND ITS 3 MAJOR PLASMA METABOLITES IN PATIENTS ENROLLED IN PHASE-I II TRIALS/, Clinical cancer research, 3(8), 1997, pp. 1261-1266
Authors:
GUIMBAUD R
BUGAT R
VANCUTSEM E
MIGNARD D
MAHJOUBI M
CANAL P
BLANC C
Citation: R. Guimbaud et al., CONSISTENT SAFETY AND EFFICACY RESULTS IN 2 STUDY POPULATIONS TREATEDWITH IRINOTECAN (CPT-11) FOR METASTATIC COLORECTAL-CANCER (MCRC) RESISTANT TO 5-FU, European journal of cancer, 33, 1997, pp. 736-736
Authors:
BENEZET S
CHATELUT E
GUIMBAUD R
CHEVREAU C
BUGAT R
CANAL P
Citation: S. Benezet et al., IS CHATELUT FORMULA APPLICABLE IN OBESE PATIENTS FOR PREDICTING CARBOPLATIN CLEARANCE, European journal of cancer, 33, 1997, pp. 1123-1123
Authors:
BENEZET S
GUIMBAUD R
CHATELUT E
CHEVREAU C
BUGAT R
CANAL P
Citation: S. Benezet et al., HOW TO PREDICT CARBOPLATIN CLEARANCE FROM STANDARD MORPHOLOGICAL AND BIOLOGICAL CHARACTERISTICS IN OBESE PATIENTS, Annals of oncology, 8(6), 1997, pp. 607-609
Authors:
BACHAUD JM
CHATELUT E
CANAL P
ALBIN N
YARDENI E
DAVID JM
SERRANO E
DALYSCHVEITZER N
Citation: Jm. Bachaud et al., RADIOTHERAPY WITH CONCOMITANT CONTINUOUS CISPLATIN INFUSION FOR UNRESECTABLE TUMORS OF THE UPPER AERODIGESTIVE TRACT - RESULTS OF A PHASE-ISTUDY, American journal of clinical oncology, 20(1), 1997, pp. 1-5
Authors:
PINGUET F
MARTEL P
FABBRO M
PETIT I
CANAL P
CULINE S
ASTRE C
BRESSOLLE F
Citation: F. Pinguet et al., PHARMACOKINETICS OF HIGH-DOSE INTRAVENOUS MELPHALAN IN PATIENTS UNDERGOING PERIPHERAL-BLOOD HEMATOPOIETIC PROGENITOR-CELL TRANSPLANTATION, Anticancer research, 17(1B), 1997, pp. 605-611
Authors:
GUICHARD S
CUSSAC D
HENNEBELLE I
BUGAT R
CANAL P
Citation: S. Guichard et al., SEQUENCE-DEPENDENT ACTIVITY OF THE IRINOTECAN-5FU COMBINATION IN HUMAN COLON-CANCER MODEL HT-29 IN-VITRO AND IN-VIVO, International journal of cancer, 73(5), 1997, pp. 729-734
Authors:
CALIARO MJ
VITAUX P
LAFON C
LOCHON I
NEHME A
VALETTE A
CANAL P
BUGAT R
JOZAN S
Citation: Mj. Caliaro et al., MULTIFACTORIAL MECHANISM FOR THE POTENTIATION OF CISPLATIN (CDDP) CYTOTOXICITY BY ALL-TRANS-RETINOIC ACID (ATRA) IN HUMAN OVARIAN-CARCINOMACELL-LINES, British Journal of Cancer, 75(3), 1997, pp. 333-340
Authors:
CANAL P
GAY C
DEZEUZE A
DOUILLARD JY
BUGAT R
BRUNET R
ADENIS A
HERAIT P
LOKIEC F
MATHIEUBOUE A
Citation: P. Canal et al., PHARMACOKINETICS AND PHARMACODYNAMICS OF IRINOTECAN DURING A PHASE-IICLINICAL-TRIAL IN COLORECTAL-CANCER, Journal of clinical oncology, 14(10), 1996, pp. 2688-2695
Citation: P. Canal et E. Chatelut, DOSE OPTIMIZATION IN CLINICAL ONCOLOGY - PHARMACOKINETIC-PHARMACODYNAMIC RELATIONSHIPS, Bulletin du cancer, 83(4), 1996, pp. 256-265